08:00 , Mar 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Lysophosphatidic acid receptor 2 (LPAR2; EDG4; LPA2)

Gastrointestinal disease INDICATION: Gastrointestinal In vitro and mouse studies suggest that an LPAR2 agonist could help treat radiation-induced gastrointestinal syndrome. A chemical screen identified a sulfamoyl benzoic acid analog that agonized LPAR2 with EC50 ~100...